 The Lassa virus, LASV, is a deadly hemorrhagic fever virus that causes chronic seizures and permanent deafness and is endemic in West Africa. An ongoing outbreak in Nigeria has resulted in 144 deaths in 568 confirmed cases as of November 2018. A DNA vaccine encoding a codeon-optimized LASV glycoprotein precursor gene, PLASV-GPC, completely protects guinea pigs and NHPs against viremia, clinical disease, and death following lethal LASV challenge. In this study, the authors report on the immunogenicity profile of the last DNA vaccine in protected NHPs, revealing that the vaccine generates functional, last specific T-cell and antibody responses. The essays developed in this study will provide a framework to identify correlates of protection and characterize immune responses in future clinical trials. This article was authored by Jingjing Jiang, Preeti Bangla, Kathleen A. Cashman, and others. We are article.tv, links in the description below.